MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
20.80
+0.72
+3.59%
After Hours: 20.81 +0.01 +0.05% 16:05 05/09 EDT
OPEN
20.75
PREV CLOSE
20.08
HIGH
22.58
LOW
20.41
VOLUME
4.68K
TURNOVER
--
52 WEEK HIGH
29.01
52 WEEK LOW
12.12
MARKET CAP
66.45M
P/E (TTM)
-6.5018
1D
5D
1M
3M
1Y
5Y
1D
These are the sectors best liked within defensive and cyclicals groups – Morgan Stanley
Seeking Alpha · 6d ago
Weekly Report: what happened at VTVT last week (0428-0502)?
Weekly Report · 6d ago
Weekly Report: what happened at VTVT last week (0421-0425)?
Weekly Report · 04/28 12:29
Weekly Report: what happened at VTVT last week (0414-0418)?
Weekly Report · 04/21 12:29
Weekly Report: what happened at VTVT last week (0407-0411)?
Weekly Report · 04/14 12:13
vTv Therapeutics Appoints Barry Brown as Interim CFO
TipRanks · 04/11 22:25
BUZZ-U.S. STOCKS ON THE MOVE-Walmart, Ford Motor, Starbucks
Reuters · 04/09 18:26
BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, U.S Steel Corp, Lincoln National
Reuters · 04/09 13:16
More
About VTVT
More
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Recently
Symbol
Price
%Change

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.